Home › Non-Muscle Invasive Bladder Cancer › North Carolina
Non-Muscle Invasive Bladder Cancer clinical trials in North Carolina
6 studies for Non-Muscle Invasive Bladder Cancer are looking for participants at sites in North Carolina.
Cities in North Carolina
Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer
- Duke Cancer Institute, Durham
- Associate Urologist of North Carolina, Raleigh
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT06995677A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
- Biorepository and Precision Pathology Center (BRPC), Durham
- Duke Cancer Institute, Durham
- Substrate Services Core Research Support (SSCRS), Durham
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07206225A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) in the United States
- Urology Specialists of the Carolinas PLLC Charlotte, Charlotte
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07309445FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
- University of North Carolina (UNC) - Chapel Hill, Chapel Hill
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 20, 2026 · NCT05614739LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
- UNC Chapel Hill Hospital, Chapel Hill
- Duke Health - Duke Cancer Center, Durham
- Associated Urologists of North Carolina, Raleigh
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 7, 2026 · NCT04752722Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2
- University of North Carolina, Chapel Hill
RecruitingObservational study
Ages 18 and older · All sexes · Updated Jul 31, 2026 · NCT07225127From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.